Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara Launches Cardiac Safety Simulator to Help Assess New Drug Candidates’ Arrhythmia Risk
August 01, 2013
Simulator helps sponsors to assess arrhythmia risk before a candidate enters clinical trials; determine safe drug doses for specific patient populations
ST. LOUIS, MO – August 1, 2013 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Cardiac Safety Simulator™ (CSS), based on an in-silico model of human ventricular heart cells. When the CSS is integrated with Certara’s Simcyp™ Population-based Simulator, it allows for the in-vitro to in-vivo extrapolation of the pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.
“Our Cardiac Safety Simulator can help to determine whether a drug candidate is likely to cause disruption of the electrical potential in the left ventricular cardiac cells and QT prolongation, which are surrogates for potentially-fatal arrhythmias, before the drug candidate enters clinical trials. This is possible because the tool’s mechanistic modeling is based on human data,” said Dr. Sebastian Polak, principal scientist at Certara’s Simcyp, associate professor at the Jagiellonian University in Cracow, Poland, and chief architect of the CSS. “This model incorporates not only information about the chemical structure of the molecule, but also independent parameters including in-vitro study settings,” he added. QT is an electrocardiogram (ECG) marker, which represents the ventricular repolarization that occurs when the heart beats.
As the CSS includes a virtual population generator, it allows sponsors to model variability between individuals as well as within them. Sponsors are no longer looking at average individuals, but at entire populations in which they can determine the number, gender and age of participants. The CSS can predict differences in response based on demographic, physiological, and genetic variations. It also factors in chronopharmacology and the fact that individuals can respond differently to a drug dose at different times of the day. Results are displayed as pseudo ECGs.
Sponsors can continue to use the CSS throughout the drug development process, further refining their cardiac risk analysis as clinical data becomes available. The CSS can also be used to help determine safe drug doses for specific patient populations.
The CSS’ initial focus will be on QT prolongation. However, there are already plans underway to include additional electrophysiology endpoints, and also heart contractility and heart muscle cell metabolism modules in the CSS.
About Certara
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives.
Certara Contact:
Diana O’Rourke, 314-951-3310
Director of Marketing
diana.orourke@certara.com
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com